This is an aggregated industry headline. Read the full story at BioPharma Dive →
Trailing rivals, AbbVie scores win with dual-acting myeloma drug
The drugmaker is leaning on a better side effect profile compared to drugs from J&J, Pfizer and Regeneron as it pushes etentamig toward FDA submission.
By BioPharma Dive
· Sep 4, 2026
· via BioPharma Dive
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineBioPharma Dive
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekBriefing
The government released 2027 Medicare Advantage quality ratings, and early coverage singled out Humana as the …
The WeekPharmaceutical Technology ↗
Perceptive Discovery and Nucleus RadioPharma have announced a non-exclusive strategic partnership to assist ra…
The WeekAJMC ↗
Using Complement Inhibitors in GA Comes With Pros and Cons…